New vaccine study aims to protect korean infants from deadly meningitis
NCT ID NCT06113198
First seen Apr 08, 2026 · Last updated May 17, 2026 · Updated 6 times
Summary
This study is testing a vaccine called MenB+OMV NZ to see if it is safe and helps protect healthy infants in Korea from meningococcal group B disease, a serious cause of meningitis. About 50 babies will receive two doses starting at 2 months old, plus a booster shot later. Researchers will measure the immune response and watch for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGITIS, MENINGOCOCCAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Incheon, 6510, South Korea
-
GSK Investigational Site
Junggu, 400711, South Korea
-
GSK Investigational Site
Kyungki-do, 14068, South Korea
-
GSK Investigational Site
Seongnam-si Gyeonggi-do, 13620, South Korea
-
GSK Investigational Site
Seoul, 02841, South Korea
-
GSK Investigational Site
Seoul, 05505, South Korea
-
GSK Investigational Site
Seoul, 07804, South Korea
-
GSK Investigational Site
Seoul, 137701, South Korea
Conditions
Explore the condition pages connected to this study.